Loading
Immunome Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by BIENAIME JEAN JACQUES, was filed 09 Jun 2026.
Insider Decl.
121
Thresholds
n/a
Buy Volume
€11M
41 ops. · all time
Sell Volume
€23M
27 ops. · all time
Who traded when
BuySaleIsaac Barchas12 sales
Bienaime Jean Jacques8 buys2 sales
Clay B. Siegall8 buys
Robert Lechleider1 buy5 sales
Philip Tsai3 buys
Max Rosett2 sales
+3 other insiders
Since the insiders bought
- -5.6%Entry US$22.45 · Close at T+90 US$21.19
- -11.6%Entry US$20.36 · Close 21 Oct 2026 US$18.00
- -4.5%Entry US$21.73 · Close at T+90 US$20.75
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Immunome Inc. Strong Buy (bullish), based on 16 analysts. Average price target: US$35.19.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$18.00
Analyst consensus
16 analystsStrong buy
US$24.00Target US$35.19(+95%)US$40.00
Income statement
RevenueUS$6.9M
EBITDA-US$221.2M-3186% margin
Net income-US$212.4M-3060.0% margin
Valuation
PER (forward)-7.3x
P/Book3.9x
Beta2.56
Balance sheet & cash
Market capUS$2.1B
Total debtUS$3.9M
Free Cash Flow-US$206.9M
Debt / Equity1%
Profitability & ownership
ROE-64.0%
ROA-37.8%
% insiders6.3%
% institutions102.8%
Last declaration on 15 September 2026
Declarations121 total
8,800 shares0Common StockSEC:0001993684-26-000008:2
18,000 shares@ US$1.350.0012% mcap3.9% of flowCommon StockSEC:0001993684-26-000008:0
13,200 shares@ US$25.320.016% mcap53.1% of flowCommonSEC144:0001959173-26-006875
10,125 shares@ US$26.070.0094% mcap1.9% of flowCommon StockSEC:0001808343-26-000010:0
62,291 shares@ US$26.230.058% mcap11.8% of flowCommon StockSEC:0001808343-26-000010:1
11,048 shares@ US$27.250.011% mcap2.2% of flowCommon StockSEC:0001808343-26-000010:2
20,840 shares@ US$26.060.019% mcap3.9% of flowCommon StockSEC:0001808343-26-000009:0
15,248 shares@ US$26.060.014% mcap2.9% of flowCommon StockSEC:0001808343-26-000009:1
108,504 shares@ US$25.520.11% mcap29.3% of flowCommonSEC144:0001628280-26-054494
90,616 shares@ US$25.090.082% mcap40.1% of flowCommon StockSEC:0001831215-26-000005:2
50,366 shares@ US$12.920.023% mcap11.5% of flowCommon StockSEC:0001831215-26-000005:0
40,250 shares@ US$10.600.015% mcap7.5% of flowCommon StockSEC:0001831215-26-000005:1
90,616 shares@ US$25.0950.082% mcap40.1% of flowCommonSEC144:0001959173-26-005624
38,250 shares0Common StockSEC:0001993684-26-000006:0
31,250 shares0Common StockSEC:0001831215-26-000004:0
180,000 shares0Common StockSEC:0001167496-26-000005:0
38,250 shares0Common StockSEC:0001831144-26-000002:0
47,250 shares0Common StockSEC:0001994071-26-000006:0
54,000 shares0Common StockSEC:0001997584-26-000006:0
38,250 shares0Common StockSEC:0002026600-26-000002:0
1,092 shares@ US$12.920.0005% mcap0.3% of flowCommon StockSEC:0001831215-26-000002:0
1,092 shares@ US$25.000.0010% mcap0.5% of flowCommonSEC144:0001959173-26-005148
83,094 shares@ US$24.110.072% mcap14.7% of flowCommon StockSEC:0001808343-26-000007:0
16,906 shares@ US$24.200.015% mcap3.0% of flowCommon StockSEC:0001808343-26-000007:1
55,000 shares@ US$8.730.017% mcap11.5% of flowCommon StockSEC:0001997584-26-000004:0
25 of 121 declarations
About Immunome Inc.
At Immunome Inc., 41 purchases weigh EUR 11.3 million (median EUR 142,042) against 27 sales worth EUR 22.8 million (median EUR 357,453): purchases make up 60% of open-market trades. Clay B. Siegall, President and CEO, signs the three largest: EUR 1,118,081 on January 31, 2025, EUR 1,018,821 on May 20, 2024 and EUR 954,126 on October 2, 2023, and 11 of his 13 filings are purchases. From May 24, 2021 to May 26, 2021, 5 filers bought EUR 1,318,153. Across the full history, 25 purchase filings are classed as clustered. Jean Jacques Bienaime and Michael Rapp, both Director, sign 10 and 8 purchases.
The largest sale is Isaac Barchas's (Director): EUR 6,900,126 on December 22, 2025, then EUR 1,869,901 on June 30, 2026. Barchas signs 12 filings, all sales. Kinney Horn (CHIEF BUSINESS OFFICER) sold EUR 1,974,355 on August 4, 2026.
Read moreShow less
Volume is heavily concentrated at the end: 57 filings in 2026, out of 121 since October 8, 2020, against 15 in 2021. Jack Higgins (Chief Scientific Officer) signs 16, 2 of them sales. The US healthcare and pharma company is worth USD 1.98 billion, with 6.3% held by insiders. Last twelve months: 70 filings, 10 purchases, 25 sales. For the 41 purchases with a result, the 90-day median is -18.9%, with 34% of results positive (recorded past, not a forecast).
